(Q44147445)

English

Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.

scientific article published on 18 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Allison R Jilbert

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

D S Miller

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

D Boyle

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

F Feng

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

G Y Reaiche

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

I Kotlarski

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

R Colonno

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

0 references

publication date

18 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

373

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

329-341

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18206204%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Kinetics of the immune response during HBV and HCV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Translation of immunological knowledge into better treatments of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Construction of recombinant fowlpox viruses as vectors for poultry vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Recombinant fowlpox virus vaccines for poultry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Comparison of field and vaccine strains of Australian fowlpox viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Hepatitis B--preventable and now treatable

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Characterization of duck leucocytes by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Immunoglobulin- and hepatitis B surface antigen-specific circulating immune complexes in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.11.032

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44147445&oldid=2107135082"